Share on StockTwits

Cambrex (NYSE:CBM) CEO Steven M. Klosk unloaded 126,257 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $22.01, for a total value of $2,778,916.57. Following the sale, the chief executive officer now directly owns 145,870 shares of the company’s stock, valued at approximately $3,210,599. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cambrex (NYSE:CBM) traded up 0.27% during mid-day trading on Thursday, hitting $22.12. 238,771 shares of the company’s stock traded hands. Cambrex has a one year low of $12.56 and a one year high of $23.88. The stock has a 50-day moving average of $21.63 and a 200-day moving average of $20.69. The company has a market cap of $678.6 million and a price-to-earnings ratio of 20.69.

Cambrex (NYSE:CBM) last released its earnings data on Tuesday, August 12th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.11. Analysts expect that Cambrex will post $1.08 EPS for the current fiscal year.

A number of analysts have recently weighed in on CBM shares. Analysts at Zacks upgraded shares of Cambrex from a “neutral” rating to an “outperform” rating in a research note on Monday, August 11th. They now have a $23.20 price target on the stock. Separately, analysts at First Analysis downgraded shares of Cambrex from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 8th. Finally, analysts at Longbow Research raised their price target on shares of Cambrex to $27.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.

Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.